---
document_datetime: 2023-09-21 17:40:53
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/flebogammadif-epar-procedural-steps-taken-authorisation_en.pdf
document_name: flebogammadif-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.4028955
conversion_datetime: 2025-12-20 13:02:21.63908
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The applicant  Instituto  Grifols  S.A.  submitted  on  05  September  2006  an  application  for  Marketing Authorisation to the European Medicines Agency  (EMEA)  for  Flebogammadif,  through  the centralised procedure under Article 3 (2) (b) of Regulation (EC) No 726/2004. The eligibility to the centralised procedure was agreed upon by the EMEA/CHMP on 29 March 2006. The eligibility to the centralised  procedure  under  Article  3(2)(b)  of  Regulation  (EC)  No  726/2004  was  based  on demonstration of significant technical innovation.

The  legal  basis  for  this  application  refers  to  Article  8.3  of  Directive  2001/83/EC,  as  amended  complete and independent application.

## Licensing status:

Flebogammadif  (Flebogamma  5%  DIF)  has  been  given  a  Marketing  Authorisation  in  US  on  21 December 2006.

The product was not licensed in any country at the time of submission of the application.

The Rapporteur and Co-Rapporteur appointed by the CHMP and the evaluation teams were: Rapporteur: Manfred Haase Co-Rapporteur: Concepci√≥n Prieto Yerro

## 2. Steps taken for the assessment of the product

- The application was received by the EMEA on 05 September 2006.
- The procedure started on 27 September 2006.
- The Rapporteur's first Assessment Report was circulated to all CHMP members on 8 December 2007. The Co-Rapporteur's first Assessment Report was circulated to all CHMP members on 12 December  2007.  In  accordance  with  Article  6(3)  of  Regulation  (EC)  No  726/2004,  the Rapporteur and Co-Rapporteur declared that they had completed their assessment report in less than 80 days.
- During  the  meeting  on  22-25  January  2007,  the  CHMP  agreed  on  the  consolidated  List  of Questions to be sent to the applicant. The final consolidated List of Questions was sent to the applicant on 25 January 2007.
- The applicant submitted the responses to the CHMP consolidated List of Questions on 12 April 2007.
- The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the List of Questions to all CHMP members on 25 May 2007.
- During the meeting on 18-21 June 2007, the CHMP, in the light of the overall data submitted and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a Marketing Authorisation to Flebogammadif on 21 June 2007. The applicant provided the letter of undertaking on the follow-up measures to be fulfilled post-authorisation on 19 June 2007.